Stockscreener 앱 받기
34.01
1.16%
0.39
전일 마감가:
$33.62
열려 있는:
$33.82
하루 거래량:
1.81M
Relative Volume:
0.34
시가총액:
$24.57B
수익:
$8.26M
순이익/손실:
$-397.91M
주가수익비율:
-67.53
EPS:
-0.5036
순현금흐름:
$-758.56M
1주 성능:
-0.58%
1개월 성능:
-13.90%
6개월 성능:
+15.72%
1년 성능:
+100.18%
1일 변동 폭
$33.70
$34.33
1주일 범위
$33.00
$35.59
52주 변동 폭
$16.00
$42.50
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
34.01 | 24.57B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
510.27 | 129.33B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.88 | 94.97B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.50 | 82.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.70 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.00 | 42.08B | 5.76B | 514.49M | 1.10B | 4.4813 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-09-17 | 개시 | Stifel | Buy |
| 2026-03-20 | 개시 | Bernstein | Outperform |
| 2025-09-02 | 개시 | Citigroup | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
At $5 a share, Arbutus Biopharma (ABUS) accepts tendered shares; Roivant retains about 19.5%. - Stock Titan
Roivant Sciences (ROIV) director exercises $4.46 options and sells 17,750 shares. - Stock Titan
Through a stock grant settlement, Frank Torti acquires 40,309 Roivant Sciences (ROIV) shares. - Stock Titan
CEO Matthew Gline holds 16.6 million shares after Roivant Sciences (ROIV) withholds 76,171 for taxes. - Stock Titan
Vesting triggers withholding of 46,879 shares from Roivant Sciences (ROIV) President Mayukh Sukhatme. - Stock Titan
After exercising $3.85 options, Eric Venker sells shares in Roivant Sciences (ROIV). - Stock Titan
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Nigeria
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Canada
After a $7.15M August sale, Roivant (ROIV) officer Eric Venker proposes another share sale. - Stock Titan
Roivant (ROIV) CAO uses 3,880 shares to cover RSU taxes - Stock Titan
Roivant Sciences (ROIV) CFO now holds 269,681 shares after RSU tax withholding - Stock Titan
Roivant Sciences (ROIV) director receives new 2027-vesting equity grant - Stock Titan
Roivant Sciences (ROIV) director now holds 8.97M shares - Stock Titan
New stock awards for Roivant Sciences (ROIV) director vest in 2027 - Stock Titan
Roivant Sciences (ROIV) grants director stock awards vesting in 2027 - Stock Titan
Roivant Sciences (ROIV) gives director new options and RSUs - Stock Titan
Director at Roivant (ROIV) receives new stock awards - Stock Titan
Roivant Sciences (NASDAQ: ROIV) director sells 4,938 shares under 10b5-1 plan - Stock Titan
Roivant Sciences (ROIV) director sells 5,112 shares under pre-set plan - Stock Titan
Roivant Sciences (ROIV) director lines up $930K stock sale - Stock Titan
Roivant Sciences (NASDAQ: ROIV) officer to sell 5,112 shares - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses stock to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant (ROIV) director uses shares to cover taxes - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover taxes - Stock Titan
ROIV gains commercial footing with LISRAYA appr... - Pluang
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story - Yahoo Finance
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Roivant Sciences (ROIV) Could Be 308% Overvalued Following Phase 2 Mosliciguat Data - simplywall.st
Roivant Sciences (ROIV) director sells stock under preset plan - Stock Titan
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILDSlideshow - Seeking Alpha
ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook - TradingView
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
ROIV: Robust pipeline advances and strong financials set the stage for multiple upcoming launches - TradingView
Roivant at Citi summit: cash-rich biotech leans on three pillars - Investing.com India
Why Did Roivant (NASDAQ:ROIV) Shares Surge on Study Results? - Kalkine Media
Roivant Sciences Company Profile & Introduction - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $46 to $55 - Moomoo
ROIV Maintains Buy Rating -- Price Target Raised to $55 - GuruFocus
Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial - Pulse 2.0
Guggenheim raises Roivant Sciences stock price target on trial data By Investing.com - Investing.com Australia
TD Cowen raises Roivant Sciences stock price target on trial data - Investing.com Australia
H.C. Wainwright raises Roivant Sciences price target on trial data - investing.com
Guggenheim raises Roivant Sciences stock price target on trial data - Investing.com
Roivant Sciences Stock Rallies 20% On Positive Phase 2 Trial Results For Pulmovant Drug - TIKR.com
Roivant Sciences stock surges on positive PH-ILD trial data By Investing.com - Investing.com Australia
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Roivant Sciences Ltd 주식 (ROIV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Epperly Melissa B, | Director |
Oct 01 '26 |
Sale |
36.10 |
17,750 |
640,861 |
14,954 |
| Venker Eric | President & Immunovant CEO |
Sep 30 '26 |
Option Exercise |
3.85 |
200,000 |
770,000 |
1,799,154 |
| Venker Eric | President & Immunovant CEO |
Sep 30 '26 |
Sale |
36.62 |
200,000 |
7,324,000 |
1,599,154 |
| Venker Eric | Officer |
Sep 30 '26 |
Proposed Sale |
36.62 |
200,000 |
7,323,556 |
0 |
| MELISSA EPPERLY | Director |
Sep 15 '26 |
Proposed Sale |
41.02 |
22,688 |
930,662 |
0 |
| Epperly Melissa B, | Director |
Sep 15 '26 |
Sale |
39.74 |
4,938 |
196,230 |
9,900 |
| MEGHAN FITZGERALD | Officer |
Sep 15 '26 |
Proposed Sale |
41.02 |
5,112 |
209,694 |
0 |
| Fitzgerald Meghan | Director |
Sep 15 '26 |
Sale |
39.74 |
5,112 |
203,152 |
36,108 |
| Fitzgerald Meghan | Director |
Sep 08 '26 |
Sale |
39.90 |
20,000 |
798,000 |
42,963 |
| MEGHAN FITZGERALD | Director |
Sep 08 '26 |
Proposed Sale |
34.93 |
20,000 |
698,600 |
0 |
3.05%
자본화:
|
볼륨(24시간):